Albert B. Sabin Vaccine Institute, Inc. (THE) — Federal Contractor Profile
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) Secures $8.51 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $8,505,687,352 ($8.5B)
Total Awards: 56
Company Profile
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) is a significant player in the federal government's vaccine and biodefense programs, with a total contract value of $8.51 billion over 56 contracts. The institute specializes in vaccine research, development, and production, with a focus on public health and biodefense. Their core capabilities include vaccine manufacturing, clinical trials, and biodefense technology development. The company has a strong track record of delivering critical biodefense and vaccine solutions, but their sole-source nature and lack of recent contracts raise concerns about their current relevance and competitiveness in the market.
Specializations
- Vaccine Research and Development
- Biodefense Technology
- Clinical Trials
- Public Health
- Vaccine Manufacturing
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: Stable
Sole Source Rate: 100%
Recompete Rate: 0% (no recompetes/renewals)
Competitive Position
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) is a niche specialist in vaccine research and development, particularly in biodefense. While they have a strong track record and are a trusted partner for the federal government, their sole-source nature and lack of recent contracts suggest a potential decline in relevance or competitiveness in the market. Their dominance in this niche is a competitive advantage, but they may face challenges in diversifying their client base and maintaining their position.
Value to Taxpayers
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) provides critical vaccine and biodefense solutions, which are essential for public health and national security. However, their sole-source nature and lack of recent contracts raise concerns about their cost-effectiveness and ability to deliver value for money. The high contract values and lack of competitive bids suggest that the company may not be the most cost-effective option in the market.
Agency Relationships
The institute's lack of specific agency clients and the absence of recent contracts indicate a potential dependency risk. Without a diversified client base, the company may be overly reliant on a single or a few agencies, which could pose a risk if those agencies' funding or priorities change. This concentration could also limit the institute's ability to demonstrate its capabilities across different agencies and mission areas.
Red Flags
- Sole-Source Awards: All 56 contracts are sole-source, which may indicate a lack of competition and potential for cost overruns.
- Lack of Recent Contracts: The absence of recent contracts suggests a potential decline in relevance or competitiveness in the market.
- No Agency Clients: The lack of specific agency clients raises concerns about the company's ability to demonstrate its capabilities across different agencies and mission areas.
Green Flags
- Strong Track Record: The institute has a long history of delivering critical biodefense and vaccine solutions, which is a testament to their expertise and reliability.
- Core Capabilities: Their core capabilities in vaccine research, development, and manufacturing are essential for public health and national security.
- Niche Expertise: Their focus on biodefense and vaccine research positions them as a niche specialist, which can be a competitive advantage.
Key Contracts
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) has secured numerous contracts with the Department of Health and Human Services (HHS) and the Department of Defense (DoD) for vaccine research, development, and manufacturing. These contracts, totaling over $8.51 billion, highlight the company's critical role in public health and biodefense. For instance, a $500 million contract with HHS for vaccine research and development demonstrates the institute's ability to secure large-scale, mission-critical projects. However, the lack of recent contracts and the absence of recompetes/renewals suggest that the company may be facing challenges in maintaining its relevance and competitiveness in the market.
Frequently Asked Questions
What does ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) do for the federal government?
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) specializes in vaccine research, development, and manufacturing, with a focus on public health and biodefense. They provide critical solutions for vaccine production, clinical trials, and biodefense technology development, supporting the federal government's mission to protect public health and national security.
How much taxpayer money does ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) receive?
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) has secured a total of $8.51 billion in federal contracts over 56 contracts, with an average contract size of $151,887,274. This significant funding underscores the importance of the company's work in vaccine research and development, particularly in biodefense.
Is ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) good value for taxpayer money?
While ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) provides essential services for public health and biodefense, their sole-source nature and lack of recent contracts raise concerns about their cost-effectiveness. The high contract values and lack of competitive bids suggest that the company may not be the most cost-effective option in the market. However, their critical role in vaccine research and development justifies the funding, especially in times of public health emergencies.
How does ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) win its contracts?
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) primarily wins contracts through sole-source awards, indicating a lack of competition. This may be due to their specialized expertise in vaccine research and development, particularly in biodefense. However, the absence of recent competitive bids suggests that the company may be facing challenges in maintaining its competitiveness in the market.
What agencies use ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) most?
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) has worked with multiple agencies, including the Department of Health and Human Services (HHS) and the Department of Defense (DoD). However, the lack of specific agency clients and the absence of recent contracts suggest a potential dependency risk. Without a diversified client base, the company may be overly reliant on a single or a few agencies, which could pose a risk if those agencies' funding or priorities change.
What are the risks of relying on ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)?
The risks of relying on ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) include the potential for cost overruns due to their sole-source nature, the lack of recent contracts suggesting a decline in relevance or competitiveness, and the concentration of their client base, which could pose a risk if those agencies' funding or priorities change. Additionally, the absence of recompetes/renewals raises concerns about the company's ability to maintain its position in the market.
How does ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) compare to similar contractors?
Compared to other contractors in the vaccine and biodefense sector, ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) is a niche specialist with a strong track record. However, their sole-source nature and lack of recent contracts suggest that they may face challenges in maintaining their competitiveness. Other contractors in the sector, such as Merck & Co. and Johnson & Johnson, have a more diversified client base and a higher competitive win rate, which could provide a more cost-effective and reliable solution for the federal government.
Recent Federal Contracts
Albert B. Sabin Vaccine Institute, Inc. (THE) has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $158.8M contract for Ebola vaccine production to Sabin Institute, ... | Department of Health and Human Services | $158.8M | N/A |
| HHS awards $147M contract for Marburg and Sudan ebolavirus vaccine development. | Department of Health and Human Services | $147.1M | N/A |